Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis

Vaccine

Volumn 28, Issue 1, 2009, Pages 53-62

  Mizbani, Amir ^a,b   Taheri, Tahereh ^a   Zahedifard, Farnaz ^a   Taslimi, Yasaman ^a   Azizi, Hiva ^a   Azadmanesh, Kayhan ^a   Papadopoulou, Barbara ^c   Rafati, Sima ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

A2 gene; Immune response; Live vaccine; Recombinant Leishmania tarentolae; Visceral leishmaniasis

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 5; LIVE VACCINE; RECOMBINANT LEISHMANIA DONOVANI A2 ANTIGEN; UNCLASSIFIED DRUG;

A2 VIRULENCE GENE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BAGG ALBINO MOUSE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE; HUMORAL IMMUNITY; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA TARENTOLAE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DNA, PROTOZOAN; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INTERFERON-GAMMA; INTERLEUKIN-5; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; TH1 CELLS; TH2 CELLS;

EID: 70849122402     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.114     Document Type: Article

References (80)

1. Badaro R., Jones T.C., and Carvalho E.M. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 154 (1986) 1003-1011
2. Pearson R.D., De Queiroz, and Sousa A. Clinical spectrum of leishmaniasis. Clin Infect Dis 22 (1996) 1-13
3. Desjeux P. Leishmania and HIV in gridlock. Publication nos. WHO/CTD/LEISH/98.9, UNAIDS/98.23. Geneva: World Health Organization; 1998.
4. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27 (2004) 305-318
5. Graham P.C.C. Introduction. In: Peters W., and Killick-Kendrick R. (Eds). The leishmaniasis in biology and medicine (1987), Academic Press, New York
6. Herwaldt B.L. Leishmaniasis. Lancet 354 (1999) 1191-1199
7. World Health Organization. Leishmania/HIV co-infection in South-Western Europe 1990-1998: retrospective analysis of 965 cases, Geneva. WHO/LEISH/2000 42 (2000) 1-12
8. Desjeux P., and Alvar J. Leishmania/HIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97 Suppl. 1 (2003) S17-S28
9. Sinha P.K., Pandey K., and Bhattacharya S.K. Diagnosis & management of Leishmania/HIV co-infection. Indian J Med Res 121 (2005) 407-414
10. World Health Organization. Advances in the battle against leishmaniasis. TDR News 57 (1998) 2
11. Croft S.L. Recent development in the chemotherapy of leishmaniasis. Trends Pharmacol Sci 9 (1988) 376-381
12. Murray H.W., Berman J.D., and Wright S.D. Immunochemotherapy for intracellular Leishmania donovani infection: γ-interferon plus pentavalent antimony. J Infect Dis 157 (1988) 973-978
13. Carter K.C., Sundar S., Spickett C., Pereira O.C., and Mullen A.B. The in vivo susceptibility of Leishmania donovani to sodium stibogluconate is drug specific and can be reversed by inhibiting glutathione biosynthesis. Antimicrob Agents Chemother 47 (2003) 1529-1535
14. Pérez-Victoria F.J., Castanys S., and Gamarro F. Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug. Antimicrob Agents Chemother 47 (2003) 2397-2403
15. Ponte-Sucre A. Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biol Dis 2 (2003) 14
16. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6 (2001) 849-854
17. Sundar S., More D.K., Singh M.K., Singh V.P., Sharma S., Makharia A., et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31 (2000) 1104-1107
18. Modabber F. Vaccines against leishmaniasis. Ann Trop Med Parasitol 89 Suppl. 1 (1995) 83-88
19. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14 (2001) 229-243
20. Sukumaran B., and Madhubala R. Leishmaniasis: current status of vaccine development. Curr Mol Med 4 (2004) 667-679
21. Connell N.D., Medina-Acosta E., McMaster W.R., Bloom B.R., and Russell D.G. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guerin expressing the Leishmania surface proteinase gp63. Proc Natl Acad Sci USA 90 (1993) 11473-11477
22. Mendonca S.C.F., Russell D.G., and Coutinho S.G. Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63). Clin Exp Immunol 83 (1991) 472-478
23. McMahon-Pratt D., Rodriguez D., Rodriguez J.-R., Zhang Y., Manson K., Bergman C., et al. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect Immun 61 (1993) 3351-3359
24. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186 (1997) 1137-1147
25. Mougneau E., Altare F., Wakil A.E., Zheng S., Coppola T., Wang Z.-E., et al. Expression cloning of a protective Leishmania antigen. Science 268 (1995) 563-566
26. Rafati S., Baba A.A., Bakhshayesh M., and Vafa M. Vaccination of BALB/c mice with Leishmania major amastigote-specific cysteine proteinase. Clin Exp Immunol 120 (2000) 134-138
27. Dole V.S., Raj V.S., Ghosh A., Madhubala R., Myler P.J., and Stuart K.D. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis. Vaccine 19 (2000) 423-430
28. Handman E., Symons F.M., Baldwin T.M., Curtis J.M., and Scheerlinck J.-P.Y. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 63 (1995) 4261-4267
29. Skeiky Y.A.W., Coler R.N., Brannon M., Stromberg E., Greeson K., Thomas Crane R., et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20 (2002) 3292-3303
30. Webb J.R., Campos-Neto A., Ovendale P.J., Martin T.I., Stromberg E.J., Badaro R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66 (1998) 3279-3289
31. Saravia N.G., Hazbón M.H., Osorio Y., Valderrama L., Walker J., Santrich C., et al. Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana. Vaccine 23 (2005) 984-995
32. Stager S., Smith D.F., and Kaye P.M. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol 165 (2000) 7064-7071
33. Skeiky Y.A.W., Kennedy M., Kaufman D., Borges M.M., Guderian J.A., Scholler J.K., et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 161 (1998) 6171-6179
34. Wilson M.E., Young B.M., Andersen K.P., Weinstock J.V., Metwali A., Ali K.M., et al. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun 63 (1995) 2062-2069
35. Champsi J., and McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 56 (1988) 3272-3279
36. Coler R.N., and Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol 21 (2005) 244-249
37. Murray H.W., Berman J.D., Davies C.R., and Saravia N.G. Advances in leishmaniasis. Lancet 366 (2005) 1561-1577
38. Piedrafita D., Xu D., Hunter D., Harrison R.A., and Liew F.Y. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major. J Immunol 163 (1999) 1467-1472
39. + regulatory T cells control Leishmania major persistence and immunity. Nature 420 (2002) 502-507
40. Uzonna J.E., Wei G., Yurkowski D., and Bretscher P. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 167 (2001) 6967-6974
41. Rivier D., Bovay P., Shah R., Didisheim S., and Mauel J. Vaccination against Leishmania major in a CBA mouse model of infection: role of adjuvants and mechanism of protection. Parasite Immunol 21 (1999) 461-473
42. Mitchell G.F., Handman E., and Spithill T.W. Vaccination against cutaneous leishmaniasis in mice using nonpathogenic cloned promastigotes of Leishmania major and importance of route of injection. Aust J Exp Biol Med Sci 62 (1984) 145-153
43. Gorczynski R.M. Immunization of susceptible BALB/c mice against Leishmania braziliensis. II. Use of temperature-sensitive avirulent clones of parasite for vaccination purposes. Cell Immunol 94 (1985) 11-20
44. + T cells which protect susceptible BALB/c mice against infection with virulent L. major. Infect Immun 61 (1993) 5205-5213
45. Daneshvar H., Coombs G.H., Hagan P., and Phillips R.S. Leishmania mexicana and Leishmania major: attenuation of wild-type parasites and vaccination with the attenuated lines. J Infect Dis 187 (2003) 1662-1668
46. Titus R.G., Gueiros-Filho F.J., De Freitas L.A.R., and Beverley S.M. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 92 (1995) 10267-10271
47. Alexander J., Coombs G.H., and Mottram J.C. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 161 (1998) 6794-6801
48. Hübel A., Krobitsch S., Hörauf A., and Clos J. Leishmania major Hsp100 is required chiefly in the mammalian stage of the parasite. Mol Cell Biol 17 (1997) 5987-5995
49. Silvestre R., Cordeiro-da-Silva A., Santarém N., Vergnes B., Sereno D., and Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFN-γ/IL-10 pattern that correlates with protection. J Immunol 179 (2007) 3161-3170
50. Uzonna J.E., Späth G.F., Beverley S.M., and Scott P. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 172 (2004) 3793-3797
51. Papadopoulou B., Roy G., Breton M., Kündig C., Dumas C., Fillion I., et al. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect Immun 70 (2002) 62-68
52. Dumas C., Ouellette M., Tovar J., Cunningham M.L., Fairlamb A.H., Tamar S., et al. Disruption of the trypanothione reductase gene of Leishmania decreases its ability to survive oxidative stress in macrophages. EMBO J 16 (1997) 2590-2598
53. Breton M., Tremblay M.J., Ouellette M., and Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 73 (2005) 6372-6382
54. Wilson V.C.L.C., and Southgate B.A. Lizard leishmania. In: Lumsden W.H., and Evans D.A. (Eds). Biology of the Kinetoplastida (1978), Academic Press, San Diego, CA 244-268
55. Breton M., Zhao C., Ouellette M., Tremblay M.J., and Papadopoulou B. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection. J Gen Virol 88 (2007) 217-225
56. Azizi H., Hassani K., Taslimi Y., Shateri Najafabadi H., Papadopoulou B., and Rafati S. Searching for virulence factors in the non-pathogenic parasite to humans Leishmania tarentolae. Parasitology 136 (2009) 723-735
57. Charest H., and Matlashewski G. Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigotestage-specific gene. Mol Cell Biol 14 (1994) 2975-2984
58. Zhang W.W., Charest H., Ghedin E., and Matlashewski G. Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani. Mol Biochem Parasitol 78 (1996) 79-90
59. Ghedin E., Zhang W.W., Charest H., Sundar S., Kenney R.T., and Matlashewski G. Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis. Clin Diagn Lab Immunol 4 (1997) 530-535
60. Fernandes A.P., Costa M.M.S., Coelho E.A.F., Michalick M.S.M., de Freitas E., Melo M.N., et al. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 26 (2008) 5888-5895
61. Ferraz Coelho E.A., Pereira Tavares C.A., Amorim Carvalho F.A., Chaves K.F., Teixeira K.N., Rodrigues R.C., et al. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection. Infect Immun 71 (2003) 3988-3994
62. Ghosh A., Labrecque S., and Matlashewski G. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 19 (2001) 3169-3178
63. Ghosh A., Zhang W.W., and Matlashewski G. Immunization with A2 protein results in amixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine 20 (2001) 59-66
64. + T cells. Vaccine 26 (2008) 4585-4593
65. Zanin F.H.C., Coelho E.A.F., Tavares C.A.P., Marques-da-Silva E.A., Silva Costa M.M., Rezende S.A., et al. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Microbes Infect 9 (2007) 1070-1077
66. Rochette A., McNicoll F., Girard J., Breton M., Leblanc E., Bergeron M.G., et al. Characterization and developmental gene regulation of a large gene family encoding amastin surface proteins in Leishmania spp. Mol Biochem Parasitol 140 (2005) 205-220
67. Papadopoulou B., Roy G., and Ouellette M. A novel antifolate resistance gene on the amplified H circle of Leishmania. EMBO J 11 (1992) 3601-3608
68. Liew F.Y., and O'Donnell C.A. Immunology of leishmaniasis. Adv Parasitol 32 (1993) 161-259
69. Miralles G.D., Stoeckle M.Y., McDermott D.F., Finkelman F.D., and Murray H.W. Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun 62 (1994) 1058-1063
70. Tripathi P., Singh V., and Naik S. Immune response to Leishmania: paradox rather than paradigm. FEMS Immunol Med Microbiol 51 (2007) 229-242
71. Amaral V.F., Teva A., Oliveira-Neto M.P., Silva A.J., Pereira M.S., Cupolillo E., et al. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem Inst Oswaldo Cruz 97 (2002) 1041-1048
72. Nylén S., Mörtberg U., Kovalenko D., Satti I., Engström K., Bakhiet M., et al. Differential induction of cellular responses by live and dead Leishmania promastigotes in healthy donors. Clin Exp Immunol 124 (2001) 43-53
73. Okwor I., Liu D., and Uzonna J. Qualitative differences in the early immune response to live and killed Leishmania major: Implications for vaccination strategies against Leishmaniasis. Vaccine 27 (2009) 2554-2562
74. + regulatory T cells in reactivation of persistent Leishmaniasis and control of concomitant immunity. J Exp Med 200 (2004) 201-210
75. Zhang W.W., and Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 39 (2001) 935-948
76. Warren H.S., Vogel F.R., and Chedid L.A. Current status of immunological adjuvants. Annu Rev Immunol 4 (1986) 369-388
77. Snapper C.M., and Paul W.E. Interferon-γ and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236 (1987) 944-947
78. Basu R., Bhaumik S., Basu J.M., Naskar K., De T., and Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. Immunology 174 (2005) 7160-7171
79. + Th1/Th2 type of immune response in murine visceral leishmaniasis. Parasitol Res 103 (2008) 1413-1419
80. Bhowmick S., Mazumdar T., and Ali N. Vaccination route that induces transforming growth factor beta production fails to elicit protective immunity against Leishmania donovani infection. Infect Immun 77 (2009) 1514-1523